REVOLUTION OF BIOSIMILAR
Bhagyashri G. Borde*, Sakshi G. Pardhi, Vaishnavi G. Ahir, Komal A. Waghmare and Vaishnavi G. Murhe
ABSTRACT
Biosimilars are defined as officially approved new version of innovator biotherapeutic products for which the patent has expired. Globally, a large number of blockbuster therapeutic products are going off patent in the next few years. Biosimilars are surmounting pharmaceutical market from last three decades and sale increasing progressively. Advances in the biotechnology lead to development and discovery of new biological product to treat various life-threatening diseases. biosimilars are biological drug that are produce after expiry of the patent of approved innovator. Biological therapies have transformed high-burden treatments. As the patent and exclusivity period for biological medicines draws to a there is a possibility for the development and authorization of biosimilars. These products boast comparable levels of safety, quality, and effectiveness to their precursor reference products, are not identical copies and should not be considered generic substitutes for the original. Biosimilars available in India include monoclonal antibodies for treating various malignant and immunological disorders, growth factors like erythropoietin and granulocyte colony stimulating factors (G-CSF) human insulins for treating diabetes mellitus etc.
Keywords: Biosimilars, Bio generics, biologic, growth factors like (G-CSF), Cancer, Human insulin, Monoclonal antibodies.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
